Dolomite Announces Microdroplet IP License Arrangements with JST
News Aug 24, 2012
Dolomite has announced that it is now a licensee of Japan Science and Technology Agency (“JST”) under JST’s microdroplet generation technology.
Dolomite is authorized to grant sublicenses under JST’s microdroplet generation technologies.
Dolomite offers a wide range of Droplet-forming devices featuring different junction geometries, channel sizes and surface properties.
Droplet based microfluidics is ideal for a wide range of applications, including compartmentalized chemistry, single cell analysis, high throughput screening, droplet PCR and emulsion studies.
As a licensee of JST's microdroplet generation technology patent families WO2002/068104 and WO2005/089921, our customers may purchase and freely use Dolomite droplet chips for R&D purposes.
As part of the IP agreement, Dolomite is authorized to grant sub-licenses under JST’s microdroplet generation technologies.
Through the innovative use of our web shop, end-users can obtain sub-licenses very simply, using only a credit card.
Licenses are issued on a per chip basis, and may be purchased in any quantity from one to one million.
Dolomite CEO Andrew Lovatt commented: “We are very pleased to be able to offer this IP-licensing service to our clients, enabling them to continue with their droplet research free from concerns about violating this fundamental IP”.
Biomillenia Leverages QIAGEN Bioinformatics in Microbiome-on-a-Chip Discovery of Unculturable MicrobesNews
Microbiome-on-a-chip technology capable of culturing, screening and isolating bacteria in single step while demonstrating targeted benefits. QIAGEN’s Microbial Genomics Pro Suite enables analysis of microbial sequences and microbiomes.READ MORE
Fast, Accurate Parasite Detection Method DevelopedNews
A research team from the University of Macau has developed a fast, accurate, and convenient point-of-care pathogen detection method with the help of a digital microfluidic system.READ MORE
Cell-weighing Method Could Help Doctors Choose Cancer DrugsNews
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple-myeloma patients.READ MORE